Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet 394:64. https://doi.org/10.1016/s0140-6736(19)30956-0
Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong NGW, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S (2017) Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw239
Carman J, Strojan P (2012) Nasopharyngeal carcinoma in Slovenia, 1990–2003 (results of treatment with conventional two-dimensional radiotherapy). Rep Pract Oncol Radiother 17:71–78. https://doi.org/10.1016/j.rpor.2012.01.002
Article PubMed PubMed Central Google Scholar
Sarmiento MP, Mejia MB (2014) Preliminary assessment of nasopharyngeal carcinoma incidence in the Philippines: a second look at published data from four centers. Chin J Cancer 33:159–164. https://doi.org/10.5732/cjc.013.10010
Article PubMed PubMed Central Google Scholar
Kanno M, Narita N, Fujimoto Y, Wakisaka N, Yoshizaki T, Kodaira T, Makita C, Sato Y, Yamazaki K, Wakaoka T, Shimode Y, Tsuji H, Kito R, Ishinaga H, Hosokawa S, Takakura H, Nishimura K, Matoba T, Fujieda S (2019) Third epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan from 2006 to 2015. Cancers. https://doi.org/10.3390/cancers11081180
Article PubMed PubMed Central Google Scholar
Tang LL, Chen YP, Mao YP, Wang ZX, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y, Ma J (2017) Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw 15:913–919. https://doi.org/10.6004/jnccn.2017.0121
Yang XL, Wang Y, Liang SB, He SS, Chen DM, Chen HY, Lu LX, Chen Y (2018) Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. BMC Cancer 18:606. https://doi.org/10.1186/s12885-018-4419-1
Article CAS PubMed PubMed Central Google Scholar
Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536–539. https://doi.org/10.1093/jnci/dji084
Article CAS PubMed Google Scholar
Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103:1761–1770. https://doi.org/10.1093/jnci/djr432
Li XY, Chen QY, Sun XS, Liu SL, Yan JJ, Guo SS, Liu LT, Xie HJ, Tang QN, Liang YJ, Wen YF, Guo L, Mo HY, Chen MY, Sun Y, Ma J, Tang LQ, Mai HQ (2019) Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur J Cancer 110:24–31. https://doi.org/10.1016/j.ejca.2018.10.020
Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12. https://doi.org/10.1016/s0360-3016(02)02724-4
Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G (2006) Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64:374–381. https://doi.org/10.1016/j.ijrobp.2005.07.968
Cao C, Jiang F, Jin Q, Jin T, Huang S, Hu Q, Chen Y, Piao Y, Hua Y, Feng X, Chen X (2018) Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension. Oral Oncol 79:27–32. https://doi.org/10.1016/j.oraloncology.2018.02.004
Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB (2004) Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 58:682–687. https://doi.org/10.1016/s0360-3016(03)01508-6
Chau RM, Teo PM, Choi PH, Cheung KY, Lee WY (2001) Three-dimensional dosimetric evaluation of a conventional radiotherapy technique for treatment of nasopharyngeal carcinoma. Radiother Oncol 58:143–153. https://doi.org/10.1016/s0167-8140(00)00336-4
Article CAS PubMed Google Scholar
Jin YN, Tang QN, Yao JJ, Xu XW, He WZ, Wang L, You YF, Peng KW, Jiang C, Xia LP (2021) The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment epstein-barr virus DNA: retrospective analysis with a large institutional-based cohort. Transl Oncol 14:100990. https://doi.org/10.1016/j.tranon.2020.100990
Article CAS PubMed Google Scholar
Liu DH, Zhou XY, Pan YG, Chen S, Ye ZH, Chen GD (2020) Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: a propensity score matching study. Cancer Med 9:1287–1297. https://doi.org/10.1002/cam4.2785
Xu T, Zhou X, Shen C, Hu C (2018) Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: based on hazard-rate and patterns of recurrence. Oral Oncol 76:61–67. https://doi.org/10.1016/j.oraloncology.2017.11.022
Ahmed Z, Kujtan L, Kennedy K, Wood V, Schomas D, Subramanian J (2019) The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: retrospective analysis of the national cancer database. Cancer Med 8:1500–1507. https://doi.org/10.1002/cam4.2033
Article CAS PubMed PubMed Central Google Scholar
Luo S, Zhao L, Wang J, Xu M, Li J, Zhou B, Xiao F, Long X, Shi M (2014) Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 36:841–847. https://doi.org/10.1002/hed.23386
Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, Tang LL, Lin AH, Li L, Ma J (2012) The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 104:331–337. https://doi.org/10.1016/j.radonc.2011.10.009
Sun Y, Tang LL, Chen L, Li WF, Mao YP, Liu LZ, Lin AH, Li L, Ma J (2012) Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system. BMC Cancer 12:68. https://doi.org/10.1186/1471-2407-12-68
Article CAS PubMed PubMed Central Google Scholar
Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O’Sullivan B, Pang ES, O SK, Au GK, Lau JT (2005) Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong nasopharyngeal cancer study group. J Clin Oncol 23:6966–6975. https://doi.org/10.1200/jco.2004.00.7542
Article CAS PubMed Google Scholar
Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20:2038–2044. https://doi.org/10.1200/jco.2002.08.149
Article CAS PubMed Google Scholar
Zhang AM, Fan Y, Wang XX, Xie QC, Sun JG, Chen ZT, Zhu B (2012) Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy. Radiother Oncol 104:279–285. https://doi.org/10.1016/j.radonc.2012.08.022
Aftab O, Liao S, Zhang R, Tang N, Luo M, Zhang B, Shahi S, Rai R, Ali J, Jiang W (2020) Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Radiat Oncol 15:66. https://doi.org/10.1186/s13014-020-01508-4
Comments (0)